2.1. Neurodegenerative diseases
The brain is a highly oxidative organ that consumes 20% of the body’s oxygen despite accounting for only 2% of the total body weight. With normal aging, the brain accumulates metals ions such as iron (Fe), zinc (Zn), and copper (Cu). Consequently, the brain is abundant in antioxidants that control and prevent the detrimental formation of reactive oxygen species (ROS) generated via Fenton chemistry involving redox-active metal-ion reduction and activation of molecular oxygen (Smith et al., 2007
). Curcumin has been shown to exhibit activity against various neurologic diseases, including AD (Lim et al., 2001
), multiple sclerosis (Natarajan and Bright, 2002
), Parkinson disease (Zbarsky et al., 2005
), epilepsy (Sumanont et al., 2006
), cerebral injury (Ghoneim et al., 2002
), age-associated neurodegeneration (Calabrese et al., 2003
), schizopherenia (Bishnoi et al., 2008
), Spongiform encephalopathies (Creutzfeld-Jakob disease) (Hafner-Bratkovic et al., 2008
), neuropathic pain (Sharma et al., 2006a
), and depression (Xu et al., 2005
Effect of curcumin on various proinflammatory diseases.
AD is a neurodegenerative disease that involves inflammation, oxidative damage, and Abeta accumulation. Inhibition of the accumulation of Abeta and the formation fibrillar (f) Abeta (fAbeta) from Abeta and the destabilization of preformed fAbeta in the central nervous system are potential therapeutic targets for the treatment of AD. In AD, an over-accumulation of Abeta is due to either an elevated generation of amyloid precursor protein (APP) or inefficient clearance of Abeta from the brain. Abeta can efficiently generate ROS in the presence of the transition metals (Cu and Fe) in vitro. Under oxidative conditions, Abeta will form stable dityrosine cross-linked dimers that are generated from free-radical attack on the tyrosine residue. There are elevated levels of urea and SDS-resistant, stable-linked Abeta oligomers as well as dityrosine cross-linked peptides and proteins in AD brain (Huang et al., 2004
) (Tschape and Hartmann, 2006
) (Smith et al., 2007
) (Annaert and De Strooper, 2002
) (Atwood et al., 2004
Extensive research has revealed that curcumin may mediate its effects against AD through the 8 mechanisms:
- Kim et al (2001) found that curcumin and its analogues demethoxycurcumin (DMC) and bis-demethoxycurcumin (BDMC) can protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from Abeta-induced oxidative stress, and these compounds were better antioxidants than alpha-tocopherol (Kim et al., 2001).
- Inflammation in AD patients is characterized by increased expression of inflammatory cytokines and activated microglia. Lim et al (Lim et al., 2001) investigated whether curcumin could affect AD-like pathology in the APPsw mice, as suggested by inflammation, oxidative damage, and plaque pathology. Curcumin significantly lowered levels of oxidized proteins and IL-1β elevated in the brains of these mice. Interestingly, with low-dose curcumin, but not with high-dose curcumin, the astrocytic marker glial fibrillary acidic protein was reduced, and insoluble Abeta, soluble Abeta, and plaque burden were significantly decreased (by 43%–50%). However, levels of APP in the membrane fraction were not reduced. Microgliosis was also suppressed in neuronal layers but not adjacent to plaques.
- In studies conducted to determine whether curcumin can modulate the formation, extension, and destabilization of fAbeta(1–40) and fAbeta(1–42) in vitro, curcumin was found to inhibit the formation and extension of fAbeta from Abeta(1–40) and Abeta(1–42); curcumin also destabilized preformed fAbeta (Ono et al., 2004).
- In animal models of AD, curcumin reduced levels of amyloid and oxidized proteins and prevented cognitive deficits. Metals can induce Abeta aggregation and toxicity and are concentrated in AD brain. Thus chelation of metals can reduce amyloid aggregation and oxidative neurotoxicity. Each Cu2+ or Fe2+ ion can bind at least 2 curcumin molecules. The interaction of curcumin with Cu and Fe suggested another potential mechanism by which it could mediate its effects against AD animal models (Baum and Ng, 2004). Because curcumin binds the redox-active metals Fe and Cu, it may also not only protect against Abeta toxicity but may also suppress inflammatory damage by preventing metal induction of NF-κB.
- That curcumin can suppress oxidative damage, inflammation, cognitive deficits, and amyloid accumulation has been established. Yang et al (Yang et al., 2005) showed that curcumin could inhibit aggregated as well as disaggregated fAbeta40. For this application, curcumin was found to be a better Abeta40 aggregation inhibitor than ibuprofen or naproxen. Curcumin decreased Abeta formation. This effect did not depend on Abeta sequence but rather on fibril-related conformation. AD and Tg2576 mice brain sections incubated with curcumin revealed preferential labeling of amyloid plaques. In vivo studies showed that curcumin injected peripherally into aged Tg2576 mice crossed the blood-brain barrier and bound plaques. When fed to aged Tg2576 mice with advanced amyloid accumulation, curcumin labeled plaques and reduced amyloid levels and plaque burden. Hence, curcumin directly binds small beta-amyloid species to block aggregation and fibril formation in vitro and in vivo. These data suggest that low-dose curcumin effectively disaggregates Abeta and prevents fibril and oligomer formation.
- Atamna and Boyle (Atamna and Boyle, 2006) showed that beta-amyloid peptide binds with heme to form a peroxidase. This action plays a major role in the cytopathologies of AD, and curcumin inhibits this peroxidase.
- Patients with AD have defects in phagocytosis of Abeta by the macrophages and in clearance of Abeta plaques. Curcumin was found to enhance Abeta uptake by macrophages of patients with AD (Zhang et al., 2006). How curcumin enhances the phagocytosis of Abeta was examined by Fiala et al (Fiala et al., 2007) who found that macrophages of a majority of patients with AD do not transport Abeta into endosomes and lysosomes and that AD monocytes do not efficiently clear Abeta from the sections of AD brain, although they phagocytize bacteria. In contrast, macrophages of normal subjects transport Abeta to endosomes and lysosomes, and monocytes of these subjects clear Abeta in AD brain sections. Upon Abeta stimulation, mononuclear cells of normal subjects upregulate the transcription of beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (MGAT3) and other genes, including Toll-like receptors (TLRs), whereas mononuclear cells of patients with AD generally downregulate these genes. Defective phagocytosis of Abeta may be related to downregulation of MGAT3, as suggested by inhibition of phagocytosis by using MGAT3 siRNA and correlation analysis. Transcription of TLR3, bditTLR4, TLR5, bditTLR7, TLR8, TLR9, and TLR10 upon Abeta stimulation is severely depressed in mononuclear cells of AD patients in comparison to those of control subjects. In mononuclear cells of some AD patients, the BDMC may enhance defective phagocytosis of Abeta, the transcription of MGAT3 and TLRs, and the translation of TLR2-4. Thus, BDMC may correct immune defects in patients with AD and provide a previously uncharacterized approach to AD immunotherapy.
- Garcia-Alloza et al (Garcia-Alloza et al., 2007) also showed that curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an AD mouse model. They found that curcumin crosses the blood-brain barrier and labels senile plaques and cerebrovascular amyloid angiopathy in APPswe/PS1dE9 mice. Moreover, systemic treatment of mice with curcumin for 7 days cleared and reduced the existing plaques, suggesting a potent disaggregation effect. Curcumin also led to a limited, but significant reversal of structural changes in dystrophic dendrites, including abnormal curvature and dystrophy size.
These studies led to a 6-month randomized, placebo-controlled, double-blind, clinical pilot study of curcumin in patients with AD (Baum et al., 2008
). Thirty four subjects started the six-month trial and 27 completed (8 subjects on 0 g, 9 on 1g, 11 on 4g curcumin per day). The serum levels of curcumin reached maximum (250 nM) at 1.5h when given with food and 270 nM at 4h when given with water. No difference was observed between 1 and 4g groups. The inability to detect any relative protective effect of curcumin, was assigned to the lack of cognitive decline in the placebo group in this 6-month trial. Curcumin group when compared with placebo control, however, showed increased plasma levels of Vitamin E and increased serum Aβ40. The latter reflects an ability of curcumin to disaggregate Aβ-deposits in the brain, thus releasing Aβ for circulation and disposal. The authors recommended, longer and larger trials to determine the efficacy of curcumin in AD patients.
2.2. Cardiovascular Diseases
Numerous reports have indicated that inflammation plays a major role in most CVDs (Hansson et al., 2006
). First, it is widely appreciated that inflammation and oxidant stress contribute to atherogenesis. Atherosclerosis is characterized by oxidative damage, which affects lipoproteins, the walls of blood vessels, and subcellular membranes. The oxidation of low-density lipoproteins (LDLs) plays an important role in the development of atherosclerosis (Ansell, 2007
) (Mach, 2005
). Second, following cardiopulmonary bypass (CPB) and cardiac global ischemia and reperfusion (I/R), pro-inflammatory cytokines regulated by NF-κB are activated and cause cardiomyocytic injury (Yeh et al., 2005
). Third, chronic transmural inflammation and proteolytic destruction of medial elastin are key mechanisms in the development of abdominal aortic aneurysms (AAAs) (McCormick et al., 2007
). Fourth, CRP, which is also regulated by NF-κB, is an inflammatory marker and a well-known predictor of CVD (Kawanami et al., 2006
). Numerous lines of evidence suggest that curcumin mediates its effects against CVDs through diverse mechanisms, several of which are discussed in this report.
Several studies have suggested that curcumin protects the heart from I/R injury (Srivastava et al., 1985
) (Manikandan et al., 2004
) (Yeh et al., 2005
). Perhaps one of the earliest reports about the effects of curcumin against CVD was by Srivastava et al (Srivastava et al., 1985
). They examined the effect of curcumin on myocardial ischemia induced by the ligation of the left descending coronary artery. Curcumin was administered 30 min before ligation, and the hearts were removed 4 h prior to coronary artery ligation and examined for glutathione (GSH), malonaldialdehyde (MDA), myeloperoxidase (MPO), superoxide dismutase (SOD), catalase (CAT), and lactate dehydrogenase (LDH). Curcumin protected the animals against decreases in the heart rate and blood pressure following ischemia. Curcumin also prevented the ischemia-induced elevation in MDA contents and LDH release. Manikandan et al (Manikandan et al., 2004
) investigated the protective effect of curcumin against isoprenaline-induced myocardial ischemia in rat myocardium. The effect of a single oral dose of curcumin, administered 30 min before and/or after the onset of ischemia, was investigated. Curcumin given before and after treatment decreased the levels of xanthine oxidase, superoxide anion, lipid peroxides (LPs), and myeloperoxidase and the levels of SOD, CAT, GSH peroxidase, and GSH-S
-transferase activities were significantly increased after curcumin treatment. Thus curcumin was found to protect rat myocardium against ischemic insult.
Following CPB and cardiac global I/R, proinflammatory genes are upregulated, and NF-κB is involved in this regulation. Whether inactivation of NF-κB could decrease myocardial I/R injury with cardioplegia during CPB, attenuate matrix metalloproteinase (MMP) activation and prevent cardiac mechanical dysfunction in rabbits was examined by Yeh et al (Yeh et al., 2005
). Postoperative expression of myocardial mRNA levels of IL-6, MCP-1, and TNF-α; post-reperfusion plasma level of troponin I; and cardiac mechanical dysfunction were significantly decreased in the curcumin groups. The myocardial levels of activated MMP-2 and -9 were also significantly reduced compared with the levels in the control group. Thus inhibition of NF-κB activation by curcumin led to suppression of the upregulation of cardiac proinflammatory genes and activation of MMPs during CPB, thereby lessening the severity of the cardiac mechanical dysfunction after global cardiac I/R injury. In another study, the same group examined whether curcumin could decrease myocardial I/R injury with cardioplegia during CPB and attenuate the apoptosis of cardiomyocytes in rabbits (Yeh et al., 2005
). They showed that curcumin significantly decreased plasma levels of IL-8, IL-10, TNF-α, and cardiac troponin I. The appearance of apoptotic cardiomyocytes significantly decreased in the curcumin groups. Thus curcumin ameliorated the surge of pro-inflammatory cytokines during CPB and decreased the occurrence of cardiomyocytic apoptosis after global cardiac I/R injury.
Nirmala and Puvanakrishnan (1996)
showed that isoproterenol-induced myocardial infaraction in rats is prevented by curcumin (Nirmala and Puvanakrishnan, 1996
) (Nirmala and Puvanakrishnan, 1996
). Histopathologic studies of the infarcted rat heart also showed a decrease in necrosis after curcumin treatment. Cardiotoxicity induced by chemotherapeutic agents in cancer patients is a common problem. Venkatesan (Venkatesan, 1998
) showed that curcumin decreased acute Adriamycin (ADR)-induced myocardial toxicity in rats. Treatment with curcumin treatment 7 days before and 2 days following administration of ADR ameliorated the cardiotoxicity, prevented the rise in serum and LDH, and induced a significant inhibition of lipid peroxidation and augmentation of endogenous antioxidants.
Another line of evidence suggested by Quiles et al showed that curcumin exhibits a potential effect against CVD where they examined the effect of curcumin in atherosclerotic rabbits (Quiles et al., 1998
). The researchers showed that curcumin exhibited protective effects as indicated by inhibition of lipoperoxidation of subcellular membranes. In another study, they showed that oral curcumin inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis (Ramirez-Tortosa et al., 1999
). Interestingly, they found that rabbits treated with 1.6 mg/kg of curcumin had lower levels of cholesterol, phospholipids, and triglycerides in LDL than those treated at a higher dose (3.2 mg/kg). In a more recent study, these researchers showed that curcumin reduces oxidative stress and attenuates aortic fatty streak development in rabbits (Quiles et al., 2002
), as indicated by lower plasma lipid peroxide and significantly higher α-tocopherol and coenzyme Q levels. Histologic results for the fatty streak lesions revealed damage in the thoracic and abdominal aorta that was significantly lower in the curcumin-treated group than in the control group.
Olszanecki et al (2005)
examined the effect of low-dose curcumin on atherosclerosis in apoE/LDL receptor (LDLR)-double knockout mice. The mice were fed a Western diet (21% fat, 0.15% cholesterol w/w, without cholic acid). Curcumin (purity ± 98%) premixed with diet was given to each mouse for 4 months at a dose of 0.3 mg/per day. In this model, curcumin inhibited atherogenesis but did not influence the concentrations of cholesterol or triglycerides in blood or animal body weight (Olszanecki et al., 2005
Vascular smooth muscle cell (VSMC) migration, proliferation, and collagen synthesis are key events in the pathogenesis of CVD. Growth factors, such as platelet-derived growth factor (PDGF) and fibroblast growth factor, which are released during vascular injury, play a pivotal role in regulating these events. Yang et al (2006)
assessed whether curcumin could inhibit PDGF-stimulated migration, proliferation, and collagen synthesis in cultured VSMCs and neointima formation after carotid artery injury in rats (Yang et al., 2006
). Curcumin inhibited PDGF-elicited VSMC migration, proliferation, and collagen synthesis assessed by chemotaxis, [3H]thymidine incorporation, and [3H]-L-proline incorporation, respectively. Curcumin also blocked PDGF-induced VSMC actin-cytoskeleton reorganization, attenuated PDGF signal transduction, and inhibited the binding of PDGF to its receptors. Carotid artery neointima formation was significantly attenuated by perivascular curcumin compared with vehicle controls 14 days after injury, characterized by reduced DNA synthesis, collagen synthesis, and PDGF receptor phosphorylation. Thus curcumin is a potent inhibitor of PDGF-stimulated VSMC functions and may play a critical role in regulating these events after vascular injury.
Ramaswami et al (2004)
showed that curcumin blocks homocysteine (HE)-induced endothelial dysfunction in porcine coronary arteries (Ramaswami et al., 2004
). They found that curcumin could effectively block HC-induced impairment of endothelium-dependent vasorelaxation, inhibit the HC-induced epithelial nitric oxide synthase (NOS) expression, and block the effect of homocysteine on superoxide anion production.
Parodi et al (2006)
examined the effect of oral administration of curcumin on proinflammatory cytokines and destructive connective tissue remodeling in experimental AAAs. Curcumin-treated mice exhibited relative decreases in aortic tissue activator protein (AP)-1 and NF-κB DNA binding activities and significantly lower aortic tissue concentrations of IL-1β, IL-6, MCP-1, and MMP-9. Curcumin suppressed the development of experimental AAAs along with the structural preservation of medial elastin fibers and reduced aortic wall expression of several cytokines, chemokines, and proteinases known to mediate aneurismal degeneration. (Parodi et al., 2006
That curcumin plays an important role in the hypertrophy of the heart is evidenced by the results of 2 recent reports (Li et al., 2008
) (Morimoto et al., 2008
). This activity is based on the ability of curcumin to inhibit histone acetyltransferase (HAT), also called p300, which plays a critical role in the progression of pathologic cardiac hypertrophy and heart failure. Li et al (2008)
showed that curcumin-blocked phenylephrin (PE) induces cardiac hypertrophy in vitro. Curcumin also prevented and reversed mouse cardiac hypertrophy induced by aortic banding (AB) and PE infusion and abrogated histone acetylation, GATA4 acetylation, and DNA-binding activity through blocking p300-HAT activity. Curcumin also blocked AB-induced inflammation and fibrosis through disrupting p300-HAT–dependent-signaling pathways (Li et al., 2008
). Similarly, Morimoto et al (2008)
showed that curcumin inhibited the hypertrophy-induced acetylation and DNA-binding abilities of GATA4, a hypertrophy-responsive transcription factor, in rat cardiomyocytes. Curcumin also disrupted the p300/GATA4 complex and repressed agonist- and p300-induced hypertrophic responses in these cells. Both the acetylated form of GATA4 and the relative levels of the p300/GATA4 complex markedly increased in rat hypertensive hearts in vivo. In 2 different heart-failure models, hypertensive heart disease in salt-sensitive Dahl rats and surgically induced myocardial infarction in rats, curcumin prevented deterioration of systolic function and heart failure-induced increases in both myocardial wall thickness and diameter (Morimoto et al., 2008
). Thus curcumin can protect against cardiac hypertrophy, inflammation, and fibrosis through suppression of p300-HAT activity and downstream GATA4, NF-κB, and other signaling pathways. Inhibition of p300-HAT activity by the nontoxic dietary compound curcumin may provide a novel therapeutic strategy for heart failure in humans.
Curcumin has also been shown to improve the blood compatibility of the rapamycin-eluting stent (Pan et al., 2007b
) (Pan et al., 2007a
). The rapamycin- and rapamycin/curcumin-loaded poly (dl-lactic acid-co-glycolic acid (PLGA) coatings were fabricated. The data showed that incorporating curcumin in rapamycin-loaded PLGA coating can significantly decrease platelet adhesion and activation, prolong clotting time, and decrease fibrinogen adsorption, thus improving the blood compatibility of rapamycin-eluting stents. This ability of curcumin can be used to fabricate a drug-eluting stent for use in preventing thrombosis formation (Pan et al., 2007b
Diabetes is a hyperglycemic disorder that affects the brain, kidney, heart, liver, and other organs. Inflammation has been shown to play a major role in development of type II diabetes (Pillarisetti and Saxena, 2004
). The role of various inflammatory cytokines and transcription factors (such as NF-κB, NRF2, PPAR-γ) and various enzymes have been implicated in this process. Both TNF and NF-κB activation have been linked with insulin resistance (Moller and Berger, 2003
). In diabetes, curcumin can suppress blood glucose levels, increase the antioxidant status of pancreatic β-cells, and enhance the activation of PPAR-γ (Nishiyama et al., 2005
). That curcumin can modulate blood sugar levels in human subjects with diabetes was shown almost 35 years ago (Srinivasan, 1972
). Years later. Babu and Srinivasan (1995)
showed in curcumin feeding in rats improves the metabolic status in diabetic conditions (Babu and Srinivasan, 1995
). That curcumin treatment can induce hypoglycemia in rats with streptozotocin (STZ)-induced diabetes has been confirmed by others (Mahesh et al., 2004
). The mechanism by which curcumin improves this situation is probably its hypocholesterolemic influence, antioxidant nature, and free-radical scavenging property. In another study, Babu and Srinivasan (1997)
showed that curcumin exhibits hypolipidemic activity in rats with STZ-induced diabetes (Babu and Srinivasan, 1997
). The decrease in cholesterol level was due exclusively to the LDL-very LDL (VLDL) fraction. A significant decrease in blood triglyceride and phospholipids was also brought about by dietary curcumin in diabetic rats. When the mechanism of hypocholesterolemic activity in dietary curcumin was examined, it was found that hepatic cholesterol-7α-hydroxylase activity was markedly higher in curcumin-fed diabetic animals, suggesting a higher rate of cholesterol catabolism in these animals (Babu and Srinivasan, 1997
). Curcumin was found to be more effective in rats than turmeric in attenuating diabetes mellitus–related changes (Arun and Nalini, 2002
). Hyperlipidemia is a complication of diabetes mellitus. The ability of curcumin to modulate the lipid profile in rats with STZ-nicotinamide-induced diabetes was investigated by Pari and Murugan (Pari and Murugan, 2007a
). Curcumin caused a significant reduction in the blood glucose levels and a significant increase in the plasma insulin levels in these rats and a significant reduction in serum and liver cholesterol, triglycerides, free fatty acids, phospholipids, HMG coenzyme A reductase activity, VLDL, and LDL cholesterol levels. The decreased serum high-density lipoprotein (HDL) cholesterol in diabetic rats was also reversed toward normalization after the treatment (Murugan and Pari, 2006
Obesity is a major risk factor for type 2 diabetes, and it is now recognized that significant inflammatory components underly the pathophysiologies of both of these conditions (Vazquez et al., 2007
). The ability of curcumin to ameliorate diabetes and inflammation in murine models of insulin-resistant obesity was examined by Weisberg et al (2008)
. Curcumin ameliorated diabetes in high-fat diet-induced obese and leptin-deficient ob/ob male C57BL/6J mice as determined by glucose and insulin tolerance testing and hemoglobin A1c percentages. Curcumin treatment also significantly reduced macrophage infiltration of white adipose tissue, increased adipose tissue adiponectin production, and decreased hepatic nuclear NF-κB activity, hepatomegaly, and markers of hepatic inflammation. Thus orally ingested curcumin reverses many of the inflammatory and metabolic dearrangements associated with obesity and improves glycemic control in mouse models of type 2 diabetes (Weisberg et al., 2008
Both curcumin and its metabolite tetrahydrocurcumin (THC) have been shown to decrease blood glucose levels, increase plasma insulin levels, and modulate hepatic key enzyme levels in STZ-induced diabetic rats(Murugan and Pari, 2005
) through modulation of oxidative stress (Murugan and Pari, 2006
) and reduction in lipids and lipid peroxidation (Murugan and Pari, 2006
). In another study, these authors showed that oral curcumin decreased the blood glucose and plasma glycoprotein levels in diabetic rats (Murugan and Pari, 2007a
). The levels of plasma insulin and tissue sialic acid were increased, whereas the levels of tissue hexose, hexosamine, and fucose were near normal in diabetic rats treated with curcumin. These findings show that the effect of THC is more prominent than that of curcumin (Murugan and Pari, 2007b
Studies have been conducted to determine whether curcumin’s direct stimulatory effect on the pancreatic beta-cell can contribute to the hypoglycemic activity of this compound. In a study by Best et al (2007)
, curcumin induced electrical activity in rat pancreatic beta-cells by activating the volume-regulated anion channel f
. Single-channel studies have indicated that activation is the result of increased channel open probability. This effect was accompanied by depolarization of the cell membrane potential, the generation of electrical activity, and enhanced insulin release (Best et al., 2007
). Curcumin also decreased beta-cell volume, presumably reflecting loss of Cl(−), and hence water, as a result of anion channel activation. These findings are consistent with the suggestion that Cl(−) fluxes play an important role in regulating beta-cell function the stimulation of beta-cell function by curcumin might contribute to the hypoglycemic actions of this compound.. Additionally, curcumin was found to induce heme oxygenase-1 expression, which has been reported to have cytoprotective effects in mouse pancreatic beta-cells (Pugazhenthi et al., 2007
). These effects were mediated through the activation of NF-E2-related factor 2 (Nrf2). Another report indicated that in addition to heme ozygenase-1, curcumin treatment enhances islet recovery by inducing heat-shock protein 70, a response protein, during cryopreservation (Kanitkar and Bhonde, 2008
Pancreatic islet cell death is the cause of deficient insulin production in diabetes mellitus. Approaches to preventing cell death have prophylactic significance in the management of hyperglycemia. Generation of oxidative stress is implicated in STZ, a beta-cell–specific, toxin-induced islet cell death. The role of curcumin in STZ-induced islet damage was examined in vitro by Meghana et al (2007)
. Curcumin retarded islet ROS generation and inhibited apoptosis, indicating that curcumin protects islets against STZ-induced oxidative stress by scavenging free radicals (Meghana et al., 2007
How curcumin mediates its hypoglycemic effects has also been examined. Curcumin was found to suppress an increase in blood glucose levels in KK-AY mice with type 2 diabetes through PPAR-γ ligand-binding activity (Kuroda et al., 2005
) (Nishiyama et al., 2005
). Increased oxidative stress and hyperglycemia has been postulated to contribute to the accelerated accumulation of advanced glycation end-products (AGEs) and the cross-linking of collagen in diabetes mellitus. Curcumin administration for the prevention of AGE-induced complications of diabetes mellitus (Sajithlal et al., 1998
). Sidhu et al showed that curcumin enhances wound healing in genetically engineered rats with STZ-induced diabetes. Curcumin was effective via both oral and topical administration and enhanced wound repair in diabetic-impaired healing (Sidhu et al., 1999
, Sidhu et al., 1998
). Another study showed that curcumin inhibits protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels (Jain, 2006). This finding provides evidence for a novel mechanism by which curcumin supplementation may prevent the cellular dysfunction associated with diabetes. Administration of curcumin to diabetic rats showed a significant beneficial effect on erythrocyte membrane-bound enzymes and antioxidant defense in addition to its antidiabetic effect (Murugan and Pari, 2007a
Diabetic neuropathic pain, an important microvascular complication in diabetes mellitus, is recognized as one of the most difficult types of pain to treat. In a study by Sharma et al (2006)
, curcumin attenuated thermal hyperalgesia in a diabetic mouse model of neuropathic pain. (Sharma et al., 2006a
) Curcumin also inhibited TNF-α and NO release in a dose-dependent manner. These results indicate an anti-nociceptive activity of curcumin, possibly through its inhibitory action on NO and TNF-α release and point to its potential to attenuate diabetic neuropathic pain. In a later study, the same authors showed the antinociceptive activity of curcumin in combination with insulin in attenuating diabetic neuropathic pain through the participation of NO and TNF-α (Sharma et al., 2007b
Diabetic retinopathy is one of the most devastating microvascular complications of longstanding type 1 and type 2 diabetes. Oxidative stress and inflammation are implicated in the pathogenesis of retinopathy in diabetes (Haidara et al., 2006
) (Kowluru and Chan, 2007
). Curcumin administration was found to prevent a diabetes-induced decrease in the antioxidant capacity and an increase in 8-OHdG and nitrotyrosine (Kowluru and Kanwar, 2007
). Curcumin also inhibited diabetes-induced elevation in the levels of IL-1β, VEGF, and NF-κB. The effects of curcumin were achieved without amelioration of the severity of hyperglycemia. In another study, curcumin was found to prevent the development of STZ-induced diabetic cataracts in rats by inhibition of hyperglycemia-induced aggregation and insolubilization of lens proteins (Suryanarayana et al., 2005
, Suryanarayana et al., 2007
). Interestingly, these authors showed that turmeric was the ocular lens, is composed of 2 subunits: αA and αB. Of these, αB-crystallin has been shown to present widely in nonlenticular tissues, whereas αA-crystallin is largely lens specific. Kumar et al (2005)
showed an elevated expression of αA- and αB-crystallins in rats with STZ-induced diabetes, and feeding curcumin to these rats attenuated the enhanced expression of αB-crystallin (Kumar et al., 2005
). Curcumin was also found to protect endothelial dysfunction in the iris tissues of STZ-induced diabetic rats (Patumraj et al., 2006
). Curcumin decreased the blood glucose, glycosylated hemoglobin, dyslipidemia, and MDA levels significantly. Neovascularization stimulated by hyperglycemia-mediated induction of VEGF has been implicated in the pathogenesis of diabetic retinopathy. The ability of curcumin to inhibit VEGF expression in rats with STZ-induced diabetic retina was examined by (Mrudula, 2007). Curcumin induced a decrease in VEGF expression in diabetic retina compared to control retina at both the transcription and protein levels.
Chronic hyperglycaemia in diabetes leads to the development of diabetic nephropathy. Sharma et al (2006)
showed that treatment with curcumin for 2 weeks significantly attenuated both renal dysfunction and oxidative stress in diabetic animals (Sharma et al., 2006b
). Curcumin was also found to improve hepatic and renal function markers and protein levels in experimental type 2 diabetic rats (Murugan and Pari, 2007b
). Curcumin reversed the diabetes-induced total protein, albumin, globulin, and albumin/globulin ratio; the activities of hepatic and renal markers; and the levels of urea, uric acid, and creatinine. Tikoo et al (2008)
examined the changes in histone modification by curcumin treatment, which prevents development of type I diabetic. At the nuclear level, curcumin prevented the decrease in dephosphorylation and the increase in acetylation of histone H3 suggesting that protection against the development of diabetic nephropathy by curcumin treatment involves changes in post-translational modifications of histone H3 (Tikoo et al., 2008
Cardiomyopathy has been associated with the pathogenesis of chronic diabetic complications. Treatment of STZ-induced diabetic rats with curcumin reduced eNOS and inducible NOS levels in association with reduced oxidative DNA and protein damage in the heart (Farhangkhoee et al., 2006
). Curcumin prevented NOS alteration and oxidative stress, which was mediated by NF-κB and AP-1. Exposure to curcumin also increased ET-1 levels in the microvascular endothelial cells. These studies indicate the differential effects of curcumin in vasoactive factor expression in the heart and indicate the importance of the tissue microenvironment in the treatment of diabetic complications.
Diabetic cardiomyopathy, structurally characterized by cardiomyocyte hypertrophy, eventually leads to heart failure. Transcriptional co-activator p300 and its interaction with myocyte enhancer factor 2 (MEF2) play a major role in diabetes-induced cardiomyocyte hypertrophy. Whether curcumin, a p300 blocker, can prevent these abnormalities, was examined by Feng et al (2008)
. Treatment with curcumin prevented diabetes-induced upregulation of these transcripts, suggesting the existence in curcumin of a novel glucose-induced epigenetic mechanism regulating gene expression and cardiomyocyte hypertrophy in diabetes (Feng et al., 2008
Emerging epidemiologic data indicate that diabetes is a potential predisposing factor for neuropsychiatric deficits such as stroke, cerebrovascular diseases, diabetic encephalopathy, depression, and anxiety. Diabetic encephalopathy, characterized by impaired cognitive functions and neurochemical and structural abnormalities, involves direct neuronal damage caused by intracellular glucose. In a study by Kuhad and Chopra (2007)
, chronic treatment with curcumin significantly attenuated cognitive deficit, cholinergic dysfunction, oxidative stress and serum levels of TNF in diabetic rats (Kuhad and Chopra, 2007
). Thus, curcumin could be used as an adjuvant therapy to conventional anti-hyperglycemic regimens for the prevention and treatment of diabetic encephalopathy. The ability of curcumin to affect the occurrence of oxidative stress in the brains of rats with diabetes was also examined. Curcumin was found to prevent brain lipid peroxidation in rats with STZ-induced diabetes (Pari and Murugan, 2007b
Altogether, these studies reveal that curcumin plays an important role in attenuating diabetes and diabetes-associated symptoms.
2.4. Allergy, asthma, and bronchitis
That allergy is a proinflammatory disease is indicated by the fact that this disease is normally mediated through inflammatory cytokines and is treated with steroids. Asthma is also an inflammatory disease in which eotaxin, MCP-1, and MCP-3 play a crucial role. These chemokines have been shown to be expressed and produced by IL-1β-stimulated human airway smooth muscle cells in culture. For instance, house dust mite is a common allergen of allergic asthma. Eosinophils are principal effector cells of allergic inflammation and their adhesion onto human bronchial epithelial cells is mediated by a CD18-intracellular adhesion molecule (ICAM)-1-dependent interaction. As shown in experiments in vivo (in guinea pigs) and in vitro (basophils), curcumin can help clear constricted airways and increase antioxidant levels. Ju et al (1996)
examined the effect of dietary fats and curcumin on immunoglobulin E (IgE)-mediated degranulation of intestinal mast cells in brown Norway rats (Ju et al., 1996
). Rats were primed intraperitoneally with β-lactoglobulin for 3 weeks to induce reaginic antibody, during which time they were fed diets containing 10% each of coconut oil (CO), high oleic safflower oil, safflower oil (SO), or fish oil and were then challenged for 3 hours orally with the antigen. The dietary SO, compared to other dietary fats, resulted in lower circulatory release of rat chymaseII (RChyII), an indicator of degranulation of mucosal mast cells in the intestine, in response to the antigen. The addition of 0.5% curcumin to the CO or SO diets lowered the release. The SO diet, compared to the CO diet, tended to increase the concentration of reaginic antibody, but the influence of curcumin was not prominent, suggesting that dietary ingredients differently influence the synthesis of IgE and degranulation of mast cells.
South et al (1997)
examined the effects of dietary curcumin (1, 20 or 40 mg/kg) for 5 weeks on antibody (IgG) production, delayed-type hypersensitivity, and natural killer cell activity in rats. The highest doses of curcumin, but not the lower doses, significantly enhanced IgG levels. Neither delayed-type hypersensitivity nor natural killer cell activity was different from control values at any dietary concentration of curcumin (South et al., 1997
To clarify the potential effect of curcumin against allergic diseases, Kobayashi et al (1997)
examined the effect of curcumin on the production of IL-2, IL-5, granulocyte macophage-colony stimulating factor (GM-CSF), and IL-4 by lymphocytes from atopic asthmatics in response to house dust mites (Dermatophagoides farinea: Df). Curcumin inhibited Df-induced lymphocyte proliferation and production of IL-2. Furthermore, curcumin inhibited IL-5, GM-CSF, and IL-4 production. These results indicate that curcumin may have a potential effect on controlling allergic diseases through inhibiting the production of cytokines affecting eosinophil function and IgE synthesis (Kobayashi et al., 1997
Ram et al (2003)
examined the anti-asthma property of curcumin in a guinea pig model of airway hyper-responsiveness (Ram et al., 2003
). Guinea pigs sensitized with ovalbumin (OVA) develop certain features characteristic of asthma: allergen-induced airway constriction and airway hyper-reactivity to histamine. Treatment with curcumin was done during sensitization (preventive) or after developing impaired airway features (therapeutic). Curcumin treatment (20 mg/kg body weight) significantly inhibited OVA-induced airway constriction and airway hyper-reactivity. The results demonstrate that curcumin is effective in improving the impaired airway features in OVA-sensitized guinea pigs.
Kurup et al used a murine model of latex allergy to investigate the role of curcumin as an immunomodulator. BALB/c mice were exposed to latex allergens and developed latex allergy with a thyroid hormone (Th)2-type immune response. These animals were treated with curcumin and the immunologic and inflammatory responses were evaluated. Animals exposed to latex showed enhanced serum IgE, latex-specific IgG1, IL-4, IL-5, IL-13, and eosinophils; and inflammation in the lungs. Intragastric treatment of latex-sensitized mice with curcumin demonstrated a diminished Th2 response with a concurrent reduction in lung inflammation. Eosinophilia in curcumin-treated mice was markedly reduced, co-stimulatory molecule expression (CD80, CD86, and OX40L) on antigen-presenting cells was decreased, and expression of MMP-9, OAT, and TSLP genes was also attenuated. These results suggest that curcumin has potential therapeutic value for controlling allergic responses resulting from exposure to allergens (Kurup and Barrios, 2008
, Kurup et al., 2007
In patients with severe asthma or chronic obstructive pulmonary disease (COPD), an inflammatory condition exists that leads to activation of the NF-κB pathway. A change also occurs in the histone acetylation and deacetylation balance via post-translational modification of histone deacetylases (HDACs). HDAC2 plays a major role in insensitivity to corticosteroid treatment in asthma and COPD. It has been shown that curcumin can restore HDAC activity, thereby restoring corticosteroid function (Marwick et al., 2007
) (Biswas and Rahman, 2008
2.5. Inflammatory bowel disease
Inflammatory bowel disease (IBD), a major risk factor for colon cancer, is characterized by oxidative and nitrosative stress, leucocyte infiltration, and upregulation of proinflammatory cytokines (Jess et al., 2005
) (Danese, 2008
). Numerous therapies used for IBD target NF-kB, which is involved in the production of cytokines and chemokines integral for inflammation. Curcumin has been shown to attenuate colitis in the dinitrobenzene sulfonic acid (DNB)-induced murine model of colitis (Salh et al., 2003
). This was accompanied by a reduction in MPO activity, IL-1β expression, and reduction of p38 MAPK. Additionally, an immunohistochemical signal was dramatically attenuated at the level of the mucosa by curcumin. Together, these results suggest that curcumin may have therapeutic implications for human IBD. Ukil et al (2003)
investigated the protective effects of curcumin on 2,4,6- trinitrobenzene sulphonic acid (TNBS)-induced colitis in mice, a model for IBD (Ukil et al., 2003
). Intestinal lesions were associated with neutrophil infiltration, increased serine protease activity, and high levels of malondialdehyde. Pretreatment of mice with curcumin (50 mg/kg daily intragastrically, for 10 days) significantly ameliorated the appearance of diarrhea and the disruption of colonic architecture. Higher doses (100 and 300 mg/kg) had comparable effects. In curcumin-pretreated mice, there was a significant reduction in the degree of both neutrophil infiltration and lipid peroxidation in the inflamed colon as well as decreased serine protease activity. Curcumin also reduced the levels of NO and O2(−) associated with the favorable expression of Th1 and Th2 cytokines and inducible NOS. Consistent with these observations, NF-κB activation in colonic mucosa was suppressed in the curcumin-treated mice, suggesting that curcumin can exert beneficial effects in experimental colitis and may, therefore, be useful in the treatment of IBD.
Jian et al (2005)
also assessed the use of curcumin in the prevention and treatment of TNBS-induced colitis in rats (Jian et al., 2005
). Sixty rats with TNBS-induced colitis were treated with 2.0% curcumin in the diet. Thirty positive control rats were treated with 0.5% sulfasalazine (SASP). Thirty negative control rats and 30 model rats were treated with a general diet. Treatment with curcumin prevented and treated both wasting and histopathologic signs of rats with TNBS-induced intestinal inflammation. In accordance with these findings, NF-kB activation in colonic mucosa was suppressed in the curcumin-treated groups. Degradations of cytoplasmic IκBα protein in colonic mucosa were blocked by curcumin treatment. Proinflammatory cytokine messenger RNA expression in colonic mucosa was also suppressed (Jian et al., 2005
Reduced bone mass is a common complication of IBD, although the mechanisms that contribute to osteopenia are not completely understood (Rodriguez-Bores et al., 2007
). TNF-α is upregulated in patients with IBD and has detrimental effects on osteoblasts. Phex gene is expressed predominantly in osteoblasts, and its disruption results in defective bone mineralization. Uno (2006)
examined whether TNF-α regulates Phex gene expression thus contributing to the abnormal bone metabolism observed in IBD (Uno et al., 2006
). Phex gene expression was evaluated in calvaria of 6- to 7-week-old mice administered TNBS with or without neutralizing anti-TNF-alpha antibody, dietary curcumin, or systemically with recombinant TNF-α. TNF-α-treated UMR-106 osteoblasts were also examined. Compared with control animals, Phex mRNA expression decreased by 40%-50% in both TNBS colitis and TNF-alpha-injected mice. Dietary curcumin and anti-TNF-α antibody counteracted the detrimental effect of TNBS on Phex gene expression. TNF-α-treated UMR-106 cells showed a decrease in Phex mRNA and gene promoter activitis. Coinciding with decreased Phex protein level, TNF-α drastically reduced mineralization in UMR-106 osteoblasts. Acute colitis and TNF-α decrease Phex mRNA and protein expression via a transcriptional mechanism. TNF-α-mediated reduction in Phex protein is at least partially responsible for inhibition of osteoblast mineralization, and the described mechanism may contribute to the abnormal bone metabolism associated with IBD.
Deguchi et al (2007)
evaluated the effects of curcumin on the development of dextran sulfate sodium (DSS)-induced experimental colitis (Deguchi et al., 2007
). BALB/c mice were fed a chow containing either 3.5% (wt/wt) DSS or 3.5% DSS + 2.0% (wt/wt) curcumin. The body weight loss was more apparent in DSS-treated mice than in DSS + curcumin-treated mice. The disease activity index, histologic colitis score, and MPO activity were all significantly higher in DSS-treated mice than in DSS + curcumin-treated mice. Microscopically, mucosal edema, cellular infiltration, and epithelial disruption were more severe in DSS-treated mice than in DSS + curcumin-treated mice. In DSS + curcumin-treated mice, NF-κB activation was blocked in the mucosa. Overall, the development of DSS-induced colitis was significantly attenuated by curcumin.
TNBS-induced colitis in NKT-deficient SJL/J mice has been described as Th1-mediated inflammation, whereas BALB/c mice are believed to exhibit a Th1/Th2 response. Billerey-Larmonier et al (2008)
investigated the effect of dietary curcumin in colitis induced in these 2 strains (Billerey-Larmonier et al., 2008
). In the BALB/c mice, curcumin significantly increased survival, prevented weight loss, and normalized disease activity. In the SJL/J mice, curcumin demonstrated no protective effects. Genome-wide microarray analysis of colonic gene expression was employed to define the differential effect of curcumin in these 2 strains. This analysis not only confirmed the disparate responses of the 2 strains to curcumin but also indicated different responses to TNBS. Curcumin inhibited proliferation of splenocytes from naive BALB/c mice but not SJL/J mice when nonspecifically stimulated in vitro with concanavalin A (ConA). Proliferation of CD4(+) splenocytes was inhibited in both strains, albeit with about a 2-fold higher IC(50) in SJL/J mice. Secretion of IL-4 and IL-5 by CD4(+) lymphocytes of BALB/c mice but not SJL/J mice was significantly augmented by Con A and reduced to control levels by curcumin. Why BALB/c strain of mice responds to curcumin and SJL/J mouse strain does not, is not clear but suggests that the therapeutic value of dietary curcumin may differ depending on the nature of immune dysregulation in IBD.
On the basis of these study results in rodents, Holt et al (2005)
performed a pilot clinical study with curcumin in patients with IBD. A pure curcumin preparation was administered in an open-label study to 5 patients with ulcerative proctitis and 5 with Crohn’s disease. All proctitis patients improved, with reductions in concomitant medications in 4, and 4 of the 5 patients with Crohn’s disease patients had lowered CDAI scores and sedimentation rates (Holt et al., 2005
). The results of this encouraging pilot study suggest the need for double-blind placebo-controlled follow-up studies.
Thus curcumin, overall, exhibits a protective role in mouse models of IBD and to reduce the relapse rate in human ulcerative colitis (UC), thus making it a potentially viable supportive treatment option.
2.6. Rheumatoid arthritis (RA) and other arthritide diseases
There are more than 100 different arthritides; however, the 3 most commonly occurring subtypes in the Western world are gout, osteoarthritis (OS), and RA. Gout occurs in response to the presence of crystals of monosodium urate in joints, bones, and soft tissues, and is treated with non-steroidal anti-inflammatory agents (NSAIDs); oral or intravenous colchicines; and oral, intravenous, or intra-articular glucocorticoids (Li, 2004
) (Liote and Ea, 2007
) (Schlesinger et al., 2006
). All are effective in aborting acute attacks of gout; however, they have severe side effects. Osteo arthritis (OA), the second most common arthritis worldwide, results from articular cartilage failure induced by a combination of genetic, metabolic, biochemical, and biomechanical factors. OA is normally treated with analgesics such as acetaminophen and opioids, NSAIDs, and intra-articular therapies such as glucocorticoids and hyaluronans.
The third most common arthritide, RA, is a chronic proinflammatory disease that is characterized by hyperplasia of the synovial fibroblasts, which is partly the result of decreased apoptosis, and joint stiffness and swelling, often manifesting in a symmetrical pattern on both sides of the body. Like most other autoimmune diseases, arthritis is more prevalent in the Western world than in other countries. Although the precise reason for this predilection is not well understood, lifestyle is known to play a major role. RA occurs in women more often than men (75% vs 25%), suggesting the role of hormones in its etiology. The roles of inflammatory cytokines, such as TNF, IL-1, IL-6, and chemokines; inflammatory enzymes such as COX-2, 5-LOX, and MMP-9; and adhesion molecules in the pathogenesis of arthritis are well documented. Almost all the mediators of inflammation linked with arthritis have been shown to be regulated by the transcription factor NF-κB. Smoking and stress are thought to contribute to RA.
The goals of management of patients with RA are to control pain and swelling, delay disease progression, minimize disability, and improve quality of life. For pain control and swelling, the treatment includes analgesics such as acetaminophen and opioids, NSAIDs, and intra-articular therapies such as glucocorticoids. In addition, diseases modifying antirheumatic drugs are used to modify the clinical and radiological courses of RA (Smolen and Aletaha, 2008a
). Examples include methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, and newer therapies such as anti-TNF-α therapy (etanercept, infliximab, and adalimumab), anti-CD20 therapy (rituximab), and abatacept. All of these agents are associated with numerous side effects (Smolen and Aletaha, 2008b
). Because current treatments for arthritis are inefficient, produce substantial side effects, and tend to be expensive, natural products, which are devoid of such disadvantages, offer a novel treatment opportunities (Hak and Choi, 2008
) (Sale et al., 2008
). Numerous reports suggest that curcumin has potential in the treatment of arthritis. Joe et al examined the effect of curcumin on acidic glycoprotein in the sera of rats with adjuvant-induced arthritis (Joe et al., 1997
). Increased levels of a glycoprotein with an apparent molecular weight of 72 kDa (Gp A72), an acidic protein with a pI of 5.1 with antitryptic activity, were observed in the sera of arthritic rats. The appearance of Gp A72 in these sera preceded the onset of paw inflammation in arthritic rats and persisted in the chronic phase. Oral administration of curcumin lowered the levels of Gp A72 by 73% with concomitant lowering of paw inflammation in arthritic rats.
Neutral matrix metalloproteinases (MMPs) are responsible for the pathologic features of RA and causes the degradation of cartilage. Onodera et al (2000)
examined the effect of curcumin on the upregulation of MMP-1 and MMP-3 mRNAs on the cultured synovial fibroblasts retrieved from patients with RA in response to MIF. They showed that mRNA upregulation of MMPs was inhibited by curcumin (Onodera et al., 2000
How curcumin could affect the immune response of the body during adjuvant-induced chronic inflammation in rats has also been investigated (Banerjee et al, 2003
). Inflammatory mediators were estimated on day 21 and day 35 after adjuvant injection. The level of CRP increased to 200% on day 21 and then reduced to 50% on day 35 compared to controls. Curcumin further reduced the increased levels at both time intervals. The haptoglobin level decreased to 42% on day 21 but increased to 5 times that of controls on day 35. Curcumin reduced the increased levels at day 35. No significant change was observed in prostaglandin-E (PGE) 2 and leukotriene-B4 levels nor in lymphocyte proliferation. The level of TNF-α increased 3-fold on day 21, but reduced to 88% on day 35. Ibuprofen treatment decreased the raised level on day 21 and increased the reduced level on day 35. IL-1β increased 2-folds on day 21 and 10-fold on day 35, both of which were significantly reduced by curcumin (Banerjee et al., 2003
). In another study, Liacini et al (2003)
showed that curcumin suppressed TNF-α-induced MMP-13 expression in primary chondrocytes; thus curcumin may reduce cartilage breakdown by MMP-13 in arthritis (Liacini et al., 2003
OA is the leading cause of disability in the Western world. COX-2 inhibitors are efficient anti-inflammatory agents commonly used in the treatment of OA (Chen et al., 2008
). However, recent studies have shown that their long-term use may be limited due to cardiovascular toxicity (Kean and Buchanan, 2005
). Whether curcumin can augment the growth-inhibitory and pro-apoptotic effects of celecoxib in OA synovial adherent cells was examined by Lev-Ari et al (2006)
. OA synovial adherent cells were prepared from human synovial tissue collected during total knee replacement surgery. A synergistic effect was observed in inhibition of cell growth when the cells were exposed to celecoxib combined with curcumin. The inhibitory effect of the combination of these drugs on cell growth resulted in an increased induction of apoptosis. The synergistic effect was mediated through a mechanism that involves inhibition of COX-2 activity. Thus the use of celecoxib at lower and safer concentrations in combination with curcumin may provide a novel combination treatment in OA and other rheumatologic disorders (Lev-Ari et al., 2006
Funk et al (2006)
examined the in vivo efficacy of curcumin in the prevention and treatment of arthritis using streptococcal cell wall–induced arthritis, a well-described animal model of RA (Funk et al., 2006
). Arthritic index, a clinical measure of joint swelling, was used as the primary end point for assessing the effect of extracts on joint inflammation. Curcumin was found to prevent joint inflammation when treatment was started before, but not after, the onset of joint inflammation. These data document the in vivo anti-arthritic efficacy of curcumin. Jackson et al recently reported that curcumin can inhibit inflammatory processes associated with arthritis (Jackson et al., 2006
Park et al (2006) showed that curcumin induces apoptosis and inhibits PGE(2) production in synovial fibroblasts of patients with RA. Curcumin caused the downregulation of anti-apoptotic Bcl-2 and the X-linked inhibitor of the apoptosis protein as well as the upregulation of pro-apoptotic Bax expression. Curcumin-induced apoptosis was also associated with the proteolytic activation of caspase-3 and caspase-9 and the concomitant degradation of poly(ADP-ribose) polymerase protein. Furthermore, curcumin decreased the expression levels of the COX-2 mRNA and protein without causing significant changes in the COX-1 levels, which was correlated with the inhibition of PGE (2) synthesis (Park et al., 2007
A clinical pilot study of curcumin 1200 mg/per day administered to a small number of patients also revealed the anti-rheumatic activity of curcumin (Deodhar et al., 1980
Psoriasis is a proinflammatory skin disease in which the roles of NF-kB, STAT3, and TNF are well documented (Aggarwal et al., 2006b
) (Liu et al., 2006
) (Abdou and Hanout, 2008
). TNF blockers have been approved for the treatment of psoriasis (Vamvouris and Hadi, 2006
). Furthermore, skin-specific STAT3 transgenic animals are known to develop psoriasis (Sano et al., 2005
). Numerous lines of evidence suggest that curcumin may be an effective treatment for psoriasis. Topical application of 1% curcumin gel to psoriatic areas reduced the density of CD8+
T cells compared to their density in untreated areas; in fact, the density of CD8+
T cells was elevated. These study results and those of others suggest that curcumin could be an effective paradigm in the treatment of psoriasis as it could also reduce the activity of PhK. Decreased PhK activity in patients with psoriasis who were treated with curcumin and calcipotriol was associated with corresponding decreases in keratinocyte transferrin receptor expression, severity of parakeratosis, and density of epidermal CD8+
T cells. These results suggest that curcumin-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histologic, and immunohistochemical criteria.
Curcumin, at a very low concentration, has been shown to be a photosensitizer in killing bacteria such as Salmonella typhimurium
and Escherichia coli
(Tonnesen et al., 1987
). The photosensitizing effects of curcumin may approve effective in the treatment of psoriasis.
Pharmacological treatments for psoriasis are generally based on antiproliferative, anti-inflammatory, or differentiation-modifying activity or some combination of these actions. Like most anti-psoriatic drugs, curcumin was found to inhibit the keratinocyte proliferation (Pol et al., 2003
), suggesting its potential in suppressing posriasis.
Kurd and colleagues (2008)
assessed the safety and efficacy of oral curcumin in patients with psoriasis. They conducted a phase II, open-label, Simon’s two-stage trial of 4.5 g/d oral curcumin in patients with plaque psoriasis. The study end points included improvement in Physicians Global Assessment score, Psoriasis Area and Severity Index score, and safety throughout the study. The intent-to-treat analysis response rate was 16.7% (95% confidence interval 2%–48%), and both responders achieved a Psoriasis Area and Severity Index score of 75. There were no study-related adverse events that necessitated participant withdrawal. The researchers concluded that large placebo-controlled studies are necessary before recommending oral curcumin as treatment for psoriasis (Kurd et al., 2008